Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H12O2 |
| Molecular Weight | 212.2439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2
InChI
InChIKey=QRZAKQDHEVVFRX-UHFFFAOYSA-N
InChI=1S/C14H12O2/c15-14(16)10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9H,10H2,(H,15,16)
Felbinac, an active metabolite of fenbufen, is two times more potent than the parent drug. Felbinac is used topically to alleviate pain in the joints and muscles caused by injury or inflammation (Trixam 3% gel or foam). The drug is believed to exert its action by inhibiting COX-2 protein.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P35354 Gene ID: 5743.0 Gene Symbol: PTGS2 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | TRAXAM Approved UseTraxam Gel is used for the relief of pain in the joints and muscles caused by injury or inflammation. It is used for the treatment of the following conditions: sprains, strains, bruising, rheumatic or arthritic conditions, frozen shoulder, tennis elbow or other joint injuries. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Biphenylacetate, but not theophylline, lethally interacts with ciprofloxacin in mice. | 1993 Nov |
|
| Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice. | 1993 Sep |
|
| Quantitation of GABAA receptor inhibition required for quinolone-induced convulsions in mice. | 1994 Nov |
|
| Role of nitric oxide in the convulsive seizures induced by fluoroquinolones coadministered with 4-biphenyl acetic acid. | 1997 Nov |
|
| Topical non-steroidal drugs are systemically absorbed and may cause renal disease. | 1999 Jan |
|
| Inhibitory effect of quinolone antimicrobial and nonsteroidal anti-inflammatory drugs on a medium chain acyl-CoA synthetase. | 2001 Aug 1 |
|
| Synthetic applications of o- and p-halobenzyl sulfones as zwitterionic synthons: preparation of ortho-substituted cinnamates and biarylacetic acids. | 2002 Jul 26 |
|
| [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration]. | 2002 Jun |
|
| Topical NSAIDs for acute pain: a meta-analysis. | 2004 May 17 |
|
| Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems. | 2006 Jan |
|
| Synthesis and pharmacological evaluation of some dual-acting amino-alcohol ester derivatives of flurbiprofen and 2-[1,1'-biphenyl-4-yl]acetic acid: a potential approach to reduce local gastrointestinal toxicity. | 2006 Nov |
|
| Percutaneous penetration of felbinac after application of transdermal patches: relationship with pharmacological effects in rats. | 2008 Jan |
|
| Stepwise two-color laser photolysis studies of alpha-cleavage in highly excited triplet states of alpha-acyl-4-phenylphenols. | 2008 Jun |
|
| Mechanisms of drug release in citrate buffered HPMC matrices. | 2009 Mar 31 |
|
| Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. | 2009 Sep 21 |
|
| Topical nonsteroidal anti-inflammatory drugs for the treatment of pain due to soft tissue injury: diclofenac epolamine topical patch. | 2010 Nov 10 |
|
| 2-(Biphenyl-4-yl)acetic acid (felbinac). | 2010 Sep 25 |
Sample Use Guides
The usual dose is about one inch or 2.5cm (which is about one gram) of gel rubbed into the affected area two to four times a day.
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
M02AA08
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
||
|
WHO-VATC |
QM02AA08
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
262307
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB07527MIG
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
100000092655
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
DB07477
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
FELBINAC
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
C80546
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
3332
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
1141
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
227-233-2
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
DTXSID0045389
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
16284
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
Y-88
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
5728-52-9
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
m5255
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL413965
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
31597
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
94WNJ5U8L7
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
5831
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY | |||
|
94WNJ5U8L7
Created by
admin on Fri Dec 15 17:35:45 GMT 2023 , Edited by admin on Fri Dec 15 17:35:45 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
